biotech · Major Depressive Disorder · Schizophrenia · NBIX
NEUROCRINE BIOSCIENCES
NEUROCRINE BIOSCIENCES INC
NEUROCRINE BIOSCIENCES patent portfolio — 27 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 6027 Edgewood Bend Ct, San Diego, California 92130, US
- Founded
- 1992
- Employees
- 2,307
- Programs
- 5
- Drugs
- 16
- Patents
- 27
NEUROCRINE BIOSCIENCES patents
27 pharmaceutical patents indexed for NEUROCRINE BIOSCIENCES. 0 expire within 24 months.
NEUROCRINE BIOSCIENCES has 27 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12128033
Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine
granted -
US 12102637
Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
granted -
US 12083227
Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
granted -
US 11730739
Treatment of congenital adrenal hyperplasia
granted -
US 11654142
Methods for the administration of certain VMAT2 inhibitors
granted -
US 11459305
Processes for the preparation of uracil derivatives
granted -
US 11439629
Methods for the administration of certain VMAT2 inhibitors
granted -
US 11311532
High dosage valbenazine formulation and compositions, methods, and kits related thereto
granted -
US 11311544
Treatment of congenital adrenal hyperplasia
granted -
US 11040029
Methods for the administration of certain VMAT2 inhibitors
granted -
US 11026939
High dosage valbenazine formulation and compositions, methods, and kits related thereto
granted -
US 11026931
Methods for the administration of certain VMAT2 inhibitors
granted -
US 10993941
Methods for the administration of certain VMAT2 inhibitors
granted -
US 10952997
Methods for the administration of certain VMAT2 inhibitors
granted -
US 10940141
Methods for the administration of certain VMAT2 inhibitors
granted -
US 10912771
Methods for the administration of certain VMAT2 inhibitors
granted -
US 10905690
Treatment of congenital adrenal hyperplasia
granted -
US 10874648
Methods for the administration of certain VMAT2 inhibitors
granted -
US 10857137
Methods for the administration of certain VMAT2 inhibitors
granted -
US 10857148
Methods for the administration of certain VMAT2 inhibitors
granted -
US 10851104
Valbenazine salts and polymorphs thereof
granted -
US 10851103
Valbenazine salts and polymorphs thereof
granted -
US 10844058
Valbenazine salts and polymorphs thereof
granted -
US 10065952
Valbenazine salts and polymorphs thereof
granted -
US 8357697
Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
granted -
US 8039627
Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
granted -
US 7419983
Gonadotropin-releasing hormone receptor antagonists and methods related thereto
granted
Frequently asked questions
How many patents does NEUROCRINE BIOSCIENCES have?
27 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do NEUROCRINE BIOSCIENCES patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.